Comparing two types of tricuspid valve replacements
Part of Heart & circulation clinical trials.
This trial compares two types of replacement valves for the tricuspid valve: a donated human valve (allograft) and a stented biological valve (made from animal tissue). The goal is to see which works better and lasts longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a disease of the tricuspid valve (the valve between the upper and lower right chambers of your heart) or a failed tricuspid valve replacement.
- You are scheduled for surgery to fix or replace the tricuspid valve.
- During surgery, the doctor decides the valve needs to be replaced instead of repaired.
- You are not pregnant.
- You do not have an active drug addiction.
- You do not have progressive HIV or a low CD4 count (below 250).
- Your tricuspid valve problem is not caused by another heart valve disease on the left side.
- Your heart's pumping strength (left ventricular ejection fraction) is at least 40%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new valve replacement device (the Cor TRICUSPID ECM Valve) for people whose right-sided tricuspid valve is leaking or missing and needs surgery. It may help restore proper one-way blood flow in the heart, but you must meet several heart, blood, and organ-health requirements.
This trial tests a new device, called the Laplace TTVR System, to replace the tricuspid valve in people whose leaky valve (tricuspid regurgitation) continues to cause symptoms despite medical treatment. It may help if you have severe symptoms and are not a candidate for open-heart surgery.
This trial tests a new device that replaces a leaky tricuspid valve (a heart valve) without open-heart surgery. If your tricuspid valve isn't working well and medicines haven't helped enough, this procedure might improve your heart function and symptoms.
This trial tests a new, less invasive valve device (TricValve) for people with severe tricuspid regurgitation who are not good candidates for open-heart surgery. It aims to see if this device can help your heart pump better and improve your symptoms.
This study tests a new way to repair the tricuspid valve (the valve that controls blood flow on the right side of your heart) using a piece of your own heart tissue called the right atrial appendage. This might be an option for people who need this type of valve surgery.
This trial tests a new catheter-based procedure that replaces the tricuspid valve to reduce severe valve leaking. It may help people who still have symptoms despite heart medicines, but only if their heart shape and other health details fit the device requirements.
Hear when a new Allograft trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.